Medtronic Inc (MDT) 75.26 $MDT
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), XON: 39.30 (+1.05), CTIC: 2.23 (-0.02), PFNX: 12.45 (+0.29), JNJ: 99.62 (+1.18), ANTM: 141.05 (-0.95), NVAX: 8.80 (+0.40), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00), TBPH: 18.51 (+0.28), SNY: 49.42 (+0.82), ALQA: 6.14 (+0.09), REGN: 402.40 (+0.66), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14), ZTS: 45.46 (-0.33), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), GERN: 3.03 (unch)
Medtronic's Reveal Cardiac Monitor: Key to AF Detection - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 2:15PM CST
The incremental cost-effectiveness ratio (ICER) associated with the utilization of Medtronic's (MDT) Reveal XT ICM came well within the cost-effectiveness range supported by the United Kingdom's National Institute of Clinical Excellence.
CSII: 35.69 (+0.17), MDT: 75.26 (+0.33), PAHC: 30.85 (+0.36), ABAX: 60.93 (+0.65)
The American Heart Association - American Stroke Association and Medtronic Collaborate to Reduce Recurrent Strokes
Thomson Reuters ONE - Fri Feb 13, 8:00AM CST
A Leading Cause of Disability and Death, Many Strokes Have No Known Cause
MDT: 75.26 (+0.33)
Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2015
Thomson Reuters ONE - Fri Feb 13, 7:00AM CST
DUBLIN - February 13, 2015 - The board of directors of Medtronic plc (NYSE:MDT) today approved a cash dividend of $0.305 per ordinary share, conditioned on receipt of Irish Court administrative approval expected to be received by early March 2015. The dividend is payable on April 17, 2015, to shareholders of record at the close of business on March 30, 2015. The quarterly dividend represents a 9% increase over the prior year. Medtronic, a constituent of the S&P 500 Dividend Aristocrats index, has committed to returning 50 percent of its free cash flow to shareholders through dividends and share repurchases.
MDT: 75.26 (+0.33)
FDA Classifies Previous Covidien Field Action for Its Trellis-6(TM) and Trellis-8(TM) Peripheral Infusion Systems As a Class 1 Recall
Thomson Reuters ONE - Thu Feb 12, 3:15PM CST
DUBLIN - February 12, 2015 - Medtronic announced today that a previously communicated global voluntary recall to address an issue with certain lots of its Trellis-6(TM) and Trellis-8(TM) peripheral infusion systems has now been classified as a Class 1 Recall by the U.S. Food and Drug Administration. Customers were previously notified by Covidien of the recall on December 15, 2014. The company has not received any reports of patient injuries related to this issue. If a patient has received treatment with a Trellis 6 or Trellis 8 from the impacted lots, no immediate action is required and physicians should continue to monitor patients in accordance with standard of care.
MDT: 75.26 (+0.33)
Study Analyzes Real-World Use of Medtronic's MiniMed 530G System
Thomson Reuters ONE - Thu Feb 12, 8:00AM CST
Diabetes Technology & Therapeutics Publishes Retrospective Analysis Detailing Impact of Threshold Suspend in Addressing Hypoglycemia
MDT: 75.26 (+0.33)
Inspire Medical Systems' Upper Airway Stimulation (UAS) Therapy is a Featured Sleep Apnea Treatment at Two Conferences
PR Newswire - Thu Feb 12, 7:00AM CST
Inspire Medical Systems, Inc., announced today that leading sleep medicine experts will discuss the company's Inspire Upper Airway Stimulation (UAS) therapy at two conferences in February. An overview of Inspire therapy will be presented at the 21st Annual Advances in Diagnosis and Treatment of Sleep Apnea and Snoring, taking place February 13-15 in Lake Buena Vista, Florida, and at the American Academy of Sleep Medicine's Sleep Medicine Trends 2015, taking place in Scottsdale, Arizona, February 20-22.
MDT: 75.26 (+0.33)
$173 Billion Wearable Technology Market Report 2015-2020 - Analysis of 221 Companies Offering 132 Different Wearable Technology Products
M2 - Thu Feb 12, 6:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/pwzm38/wearable) has announced the addition of the "Wearable Technology: 2015" report to their offering. Wearable technology will be worth USD 22.7 billion in 2015 rising to USD 173.3 billion by 2020, but the long-term potential of the sector will make these numbers seem rather small. The wearable technology market currently contains the following product segments: body sensors, smart watches, smart glasses, personal video recorders, electronic apparel and jewellery. These products are being used for the following purposes: health and activity tracking, sports performance monitors, wearable web, healthcare, life logging, location tracking and fashion and protective apparel. All these segments are included in this report. The report includes forecasts from 2014 to 2020 for smart watches, smart glasses, fitness and activity trackers and sports performance monitors. You will find very clear and detailed explanations of these and a wide range of other segments of the wearable technology market - plus plenty of examples of companies and products that occupy each of these segments. This report also contains a detailed review and status report for the main enabling technologies that will take the wearables market to the next level: ECG, body power, multi-function earbuds, thought control, electronic contact lenses and bio sensors (ingestibles and implants). You will also be able to read a very clear and detailed analysis of the future direction of the wearable technology market which will see the sector evolve from a largely device-focused industry into something far larger and more exciting. Key Topics Covered: 1. Executive Summary 2. Introduction: Market Segmentation 3. Market Developments: Last 12 Months 4. Wearable Technology Company Profiles 5. Future: Important Enabling Technologies 6. Market Analysis 7. Two $1 Trillion Wearables Opportunities 8. Market Forecasts Companies Mentioned - Abbott Laboratories - Adidas - Apple Watch - Casio - Ezio - FiLIP Technologies - Fitbit - Fitbug - Garmin - Google - Huawei B1 TalkBand - Intel - Jawbone - LG - Lenovo - Medtronic - Microsoft - Misfit Wearables - Motorola Mobility - Nike - Nissan - Omega Wave - Pebble - Pivothead - Polar - Qualcomm - Samsung - Sony - TomTom For more information visit http://www.researchandmarkets.com/research/pwzm38/wearable
ABT: 46.09 (+0.87), MDT: 75.26 (+0.33), QCOM: 70.88 (+0.49), GRMN: 55.93 (+0.02)
Medtronic reports February 17
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 3:11PM CST
MDT: 75.26 (+0.33)
Medtronic to Announce Financial Results for Its Third Quarter of Fiscal Year 2015
Thomson Reuters ONE - Wed Feb 11, 3:00PM CST
DUBLIN - Feb 11, 2015 - Medtronic plc (NYSE: MDT) announced today it will report financial results for Medtronic, Inc.'s third quarter of its fiscal year 2015 on Tuesday, February 17, 2015. A news release will be issued at approximately 6:15 a.m. Central Standard Time and will be available at http://newsroom.medtronic.com. The earnings news release will include summary financial information for Medtronic Inc.'s third fiscal quarter, which ended January 23, 2015.
MDT: 75.26 (+0.33)
Addition of Stent Thrombectomy in Treatment of Acute Ischemic Stroke Patients Reduces Disability in Global Studies
Business Wire - Wed Feb 11, 11:18AM CST
Research presented today at the International Stroke Conference (ISC) in Nashville, Tenn. and published online in The New England Journal of Medicine (NEJM) found that the addition of the Solitaire(TM) Device stent thrombectomy procedure to current pharmaceutical treatment significantly reduced disability in patients suffering stroke.
MDT: 75.26 (+0.33)
Global Insulin Delivery Devices Market 2014-2018: Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche and Becton, and Dickinson and Co Account for 90% of Global Share
M2 - Wed Feb 11, 9:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/hjxrhm/global_insulin) has announced the addition of the "Global Insulin Delivery Devices Market Outlook 2018" report to their offering. This study thus leads to the proposition that innovation has huge scope in the field of insulin delivery and its analysts have elaborate information on some of the emerging insulin delivery devices. Finally, an analysis of the leading market players provides a holistic understanding to the reader. Players covered include Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche and Becton, and Dickinson and Co. These players together account for more than 90% of the global market. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Global Insulin Market Overview to 2018 4. Industry Trends and Drivers 5. Key Market Restraints 6. Global Insulin Delivery Devices Market Outlook to 2018 7. Insulin Delivery Devices: Current and Future Outlook to 2018 8. Emerging Devices 9. Key Players - Abbott Laboratories - B. Braun Melsungen AG - Becton Dickinson - Eli Lilly - F. Hoffmann La Roche - Insulet Corporation - Johnson and Johnson - Medtronic - Novo Nordisk - Sanofi-Aventis - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/hj...al_insulin
JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87), PODD: 32.00 (-0.07), NVO: 43.76 (+0.61), MDT: 75.26 (+0.33), LLY: 70.56 (+0.03)
Device Maker Medtronic, Inc. Agrees to $2.8 Million Settlement Brought Over False Claims Allegations Involving SubQ Stimulation Procedures, Parker Waichman LLP Comments
PRWeb - Wed Feb 11, 9:04AM CST
Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective medical devices and unapproved medical procedures, is commenting on a recent settlement in a case involving Medtronic Inc. and "SubQ Stimulation" procedures. The case--United States ex rel. Nickel v. Medtronic, Inc. Civ. No. 09 - CV - 0203-S (W.D.N.Y.). (rml) NY--ended with Medtronic agreeing to pay $2.8 Million to Resolve False Claims Act Allegations, according to a February 6, 2015 U.S. Department of Justice (DOJ) report.
MDT: 75.26 (+0.33)
Congratulations Covidien: You Escaped In Time
Chris DeMuth Jr. - Seeking Alpha - Wed Feb 11, 8:19AM CST
Originally published on February 4, 2015 The Shakedown In 2014, Obama vowed to punish tax inverting companies by any means necessary - inside and outside of legislation. He took scalps including Shire (NASDAQ: SHPG ) and Walgreens (NASDAQ: WBA...
VRX: 167.00 (-0.50), WBA: 78.73 (-1.23), MDT: 75.26 (+0.33), COV: 106.71 (-1.36), SHPG: 239.82 (+6.11), SLXP: 152.35 (+3.17), NPSP: 45.88 (+0.03), ABBV: 58.05 (+1.00)
Medtronic Insertable Cardiac Monitors Detect Atrial Fibrillation in Stroke Patients in 'Real-World' Study
Thomson Reuters ONE - Wed Feb 11, 8:12AM CST
Findings Reinforce Patient Benefit of Reveal LINQ in Real-World Setting
MDT: 75.26 (+0.33)
Patient Monitoring Global Market 2015 - Forecast to 2020
M2 - Tue Feb 10, 8:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/vvvf8m/patient) has announced the addition of the "Patient Monitoring Global Market - Forecast to 2020" report to their offering. The global patient monitoring devices market is expected to reach approximately $24 billion by 2019 growing at CAGR of around 8.0%. North America commands the largest share and is expected to register a healthy market share by 2019. APAC is going to be one of the prominent regions for this market in coming years driven by the increased purchasing power and rising population. Patient monitoring is essential part of care process together with administration of therapy. The main aim of monitoring is to make sure that proper care [or] therapy can be given in advance to the arrival of complications. Patient monitoring is essential to take care in emergency and operating rooms, intensive and critical care units and it is extremely useful for recovery rooms, respiration therapy, radiology, outpatient care, and gastroenterology department, Transport, Home and sleep screening applications. Patient monitoring play key role to reduce complications, risks, infections as well assist in providing for patient comfort. Patient monitoring devices market is mainly divided into following segments such as Hemodynamic, neurology, respiratory, Cardiology, fetal and neonatal, multi parameters, remote patient monitors, temperature and weight monitors. Some of the key players in this market are Abbott Laboratories (U.S.), GE Health care (U.K.), Johnson & Johnson, Inc. (U.S.), Covidien (Ireland), Mindray Medical (China), Philips Healthcare (Netherlands), Drager Medical GmbH (Germany), and Roche Diagnostics Limited (Switzerland). Key Topics Covered: 1 Executive Summary 2 Introduction 3 Market Analysis 4 Global Patient Monitoring System Market, By Device 5 Global Patient Monitoring System Market, By End-Users 6 Regional Market Analysis 7 Company Developments 8 Major Company Profiles - Abbott Laboratories - Boston Scientific Corpoartion - Covidien Plc - Ge Healthcare - Johnson & Johnson - Medtronic Inc. - Omron Healthcare, Inc. - Philips Healthcare - Roche Ltd. - St. Jude Medical, Inc. Visit http://www.researchandmarkets.com/research/vvvf8m/patient
BSX: 14.98 (+0.24), JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87), MDT: 75.26 (+0.33), STJ: 67.48 (+0.65)
British Journal of Surgery Publishes Five-Year ClosureFast(TM) Study Results
Thomson Reuters ONE - Tue Feb 10, 8:04AM CST
Results Demonstrate Durability, Effectiveness of Treatment for Chronic Venous Insufficiency
MDT: 75.26 (+0.33)
Global Angiography Devices (Angiography systems, Catheters, Guide-Wires, Balloons, Contrast Media, Accessories) Market 2014-2019
M2 - Tue Feb 10, 5:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/66llkk/angiography) has announced the addition of the "Angiography Devices Market by Technology, Products, Application & End-Users - Global Forecast to 2019" report to their offering. The global angiography devices market is estimated to reach $27.7 billion in 2019, at a CAGR of 4.4% from 2014 to 2019 Angiography is a medical imaging procedure used to visualize blood vessels (arteries and veins) inside the body. Angiography devices are used to diagnose and evaluate many diseases of blood vessels and related conditions, such as injuries, aneurysms (ballooning of a blood vessel), blockages (due to blood clots or plaques), stenosis (narrowing of a blood vessel), congenital (birth-related) heart abnormalities, disorganized blood vessels, and blood supply to tumors. Images captured trough angiography is called as angiograms. The angiography devices market is mainly driven by technological advances, innovative product offerings, and growing aging population and increasing prevalence of vascular diseases. However, the lack of reimbursement for these systems and the presence of stringent regulations are expected to restrain the growth of this market in the forecast period. The angiography devices market in this report is broadly segmented by technology, products, applications, procedures, indications, and end users. The market, by products, is segmented into angiography systems, catheters, guide-wires, balloons, contrast media, vascular closure devices, and accessories. The market by technology is segmented into X-ray, computed tomography, and magnetic resonance angiography. Based on applications the market is segmented as diagnostic and therapeutic. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Angiography Devices Market, By Technology 7 Angiography Devices Market, By Products 8 Angiography Devices Market, By Type Of Application 9 Angiography Devices Market, By Procedure 10 Angiography Devices Market, By Indication 11 Angiography Devices Market, By End-Users 12 Geography Analysis 13 Competitive Landscape 14 Company Profiles - Abbott Vascular - Boston Scientific Corporation - Cordis Corporation (A Jnj Company) - GE Healthcare - Medtronic Inc. - Philips Healthcare - ST. Jude Medical - Shimadzu Corporation - Siemens Healthcare - Toshiba Corporation For more information visit http://www.researchandmarkets.com/research/66...ngiography
BSX: 14.98 (+0.24), MDT: 75.26 (+0.33), STJ: 67.48 (+0.65)
U.S. & European Heart Valve Market Overview 2014
M2 - Tue Feb 10, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/l83sqr/u_s_and_european) has announced the addition of the "U.S. & European Heart Valve Market" report to their offering. The surgical heart valve market consists of both mechanical and tissue heart valves. Tissue heart valves consist of stented, stentless and sutureless tissue heart valves. Stented heart valves have long been the industry standard; however, stentless and sutureless valves are expected to show a strong presence over the forecast period. A sutureless valve differs from traditional tissue heart valves in that it is self-anchoring and thus does not need to be sutured in place. Thus, sutureless heart valves require a shorter procedure time than traditional tissue heart valves, and are able to be delivered minimally invasively. The sutureless heart valve market is expected to increase its share approximately threefold. The market has a competitive landscape with each competitor having quality and clinically supported products available. A critical note for the surgical heart valve market is that the growth of the transcatheter heart valve implantation device market has not had a substantial impact on the demand for surgical heart valves, indicating that the various valve technologies treat different patient populations. Key Topics Covered: 1. Research Methodology 2. Heart Valve Device And Procedure Overview 3. U.S. Tissue Heart Valve Market 4. European Tissue Heart Valve Market 5. U.S. Mechanical Heart Valve Market 6. European Mechanical Heart Valve Market 7. U.S. Annuloplasty Repair Device Market 8. European Annuloplasty Repair Device Market 9. U.S. Transcatheter Mitral Valve Repair Device Market 10. European Transcatheter Mitral Valve Repair Market 11. U.S. Transcatheter Heart Valve Implantation Device Market 12. European Transcatheter Heart Valve Implantation Device Market Companies Mentioned - Cardiac Dimensions - Cardiosolutions - CryoLife - Direct Flow Medical - Edwards LifeSciences - Endovalve Inc - JenaValve - JenaValve Technology - Medtronic - MiCardia - Sandra Medical - Sorin - St. Jude Medical For more information visit http://www.researchandmarkets.com/research/l8...d_european
MDT: 75.26 (+0.33), STJ: 67.48 (+0.65), EW: 134.23 (+1.89), CRY: 11.30 (-0.10)
Medtronic's Pipeline Flex Embolization Device Gets FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 4:05PM CST
Medtronic announced the FDA approval for its Pipeline Flex embolization device (the next-generation flow diversion device).
ICUI: 88.98 (+0.42), NXTM: 17.56 (-0.05), MDT: 75.26 (+0.33), ABAX: 60.93 (+0.65)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), XON: 39.30 (+1.05), CTIC: 2.23 (-0.02), PFNX: 12.45 (+0.29), JNJ: 99.62 (+1.18), ANTM: 141.05 (-0.95), NVAX: 8.80 (+0.40), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00), TBPH: 18.51 (+0.28), SNY: 49.42 (+0.82), ALQA: 6.14 (+0.09), REGN: 402.40 (+0.66), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14), ZTS: 45.46 (-0.33), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), GERN: 3.03 (unch)
Medtronic's Reveal Cardiac Monitor: Key to AF Detection - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 2:15PM CST
The incremental cost-effectiveness ratio (ICER) associated with the utilization of Medtronic's (MDT) Reveal XT ICM came well within the cost-effectiveness range supported by the United Kingdom's National Institute of Clinical Excellence.
CSII: 35.69 (+0.17), MDT: 75.26 (+0.33), PAHC: 30.85 (+0.36), ABAX: 60.93 (+0.65)
The American Heart Association - American Stroke Association and Medtronic Collaborate to Reduce Recurrent Strokes
Thomson Reuters ONE - Fri Feb 13, 8:00AM CST
A Leading Cause of Disability and Death, Many Strokes Have No Known Cause
MDT: 75.26 (+0.33)
Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2015
Thomson Reuters ONE - Fri Feb 13, 7:00AM CST
DUBLIN - February 13, 2015 - The board of directors of Medtronic plc (NYSE:MDT) today approved a cash dividend of $0.305 per ordinary share, conditioned on receipt of Irish Court administrative approval expected to be received by early March 2015. The dividend is payable on April 17, 2015, to shareholders of record at the close of business on March 30, 2015. The quarterly dividend represents a 9% increase over the prior year. Medtronic, a constituent of the S&P 500 Dividend Aristocrats index, has committed to returning 50 percent of its free cash flow to shareholders through dividends and share repurchases.
MDT: 75.26 (+0.33)
FDA Classifies Previous Covidien Field Action for Its Trellis-6(TM) and Trellis-8(TM) Peripheral Infusion Systems As a Class 1 Recall
Thomson Reuters ONE - Thu Feb 12, 3:15PM CST
DUBLIN - February 12, 2015 - Medtronic announced today that a previously communicated global voluntary recall to address an issue with certain lots of its Trellis-6(TM) and Trellis-8(TM) peripheral infusion systems has now been classified as a Class 1 Recall by the U.S. Food and Drug Administration. Customers were previously notified by Covidien of the recall on December 15, 2014. The company has not received any reports of patient injuries related to this issue. If a patient has received treatment with a Trellis 6 or Trellis 8 from the impacted lots, no immediate action is required and physicians should continue to monitor patients in accordance with standard of care.
MDT: 75.26 (+0.33)
Study Analyzes Real-World Use of Medtronic's MiniMed 530G System
Thomson Reuters ONE - Thu Feb 12, 8:00AM CST
Diabetes Technology & Therapeutics Publishes Retrospective Analysis Detailing Impact of Threshold Suspend in Addressing Hypoglycemia
MDT: 75.26 (+0.33)
Inspire Medical Systems' Upper Airway Stimulation (UAS) Therapy is a Featured Sleep Apnea Treatment at Two Conferences
PR Newswire - Thu Feb 12, 7:00AM CST
Inspire Medical Systems, Inc., announced today that leading sleep medicine experts will discuss the company's Inspire Upper Airway Stimulation (UAS) therapy at two conferences in February. An overview of Inspire therapy will be presented at the 21st Annual Advances in Diagnosis and Treatment of Sleep Apnea and Snoring, taking place February 13-15 in Lake Buena Vista, Florida, and at the American Academy of Sleep Medicine's Sleep Medicine Trends 2015, taking place in Scottsdale, Arizona, February 20-22.
MDT: 75.26 (+0.33)
$173 Billion Wearable Technology Market Report 2015-2020 - Analysis of 221 Companies Offering 132 Different Wearable Technology Products
M2 - Thu Feb 12, 6:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/pwzm38/wearable) has announced the addition of the "Wearable Technology: 2015" report to their offering. Wearable technology will be worth USD 22.7 billion in 2015 rising to USD 173.3 billion by 2020, but the long-term potential of the sector will make these numbers seem rather small. The wearable technology market currently contains the following product segments: body sensors, smart watches, smart glasses, personal video recorders, electronic apparel and jewellery. These products are being used for the following purposes: health and activity tracking, sports performance monitors, wearable web, healthcare, life logging, location tracking and fashion and protective apparel. All these segments are included in this report. The report includes forecasts from 2014 to 2020 for smart watches, smart glasses, fitness and activity trackers and sports performance monitors. You will find very clear and detailed explanations of these and a wide range of other segments of the wearable technology market - plus plenty of examples of companies and products that occupy each of these segments. This report also contains a detailed review and status report for the main enabling technologies that will take the wearables market to the next level: ECG, body power, multi-function earbuds, thought control, electronic contact lenses and bio sensors (ingestibles and implants). You will also be able to read a very clear and detailed analysis of the future direction of the wearable technology market which will see the sector evolve from a largely device-focused industry into something far larger and more exciting. Key Topics Covered: 1. Executive Summary 2. Introduction: Market Segmentation 3. Market Developments: Last 12 Months 4. Wearable Technology Company Profiles 5. Future: Important Enabling Technologies 6. Market Analysis 7. Two $1 Trillion Wearables Opportunities 8. Market Forecasts Companies Mentioned - Abbott Laboratories - Adidas - Apple Watch - Casio - Ezio - FiLIP Technologies - Fitbit - Fitbug - Garmin - Google - Huawei B1 TalkBand - Intel - Jawbone - LG - Lenovo - Medtronic - Microsoft - Misfit Wearables - Motorola Mobility - Nike - Nissan - Omega Wave - Pebble - Pivothead - Polar - Qualcomm - Samsung - Sony - TomTom For more information visit http://www.researchandmarkets.com/research/pwzm38/wearable
ABT: 46.09 (+0.87), MDT: 75.26 (+0.33), QCOM: 70.88 (+0.49), GRMN: 55.93 (+0.02)
Medtronic reports February 17
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 3:11PM CST
MDT: 75.26 (+0.33)
Medtronic to Announce Financial Results for Its Third Quarter of Fiscal Year 2015
Thomson Reuters ONE - Wed Feb 11, 3:00PM CST
DUBLIN - Feb 11, 2015 - Medtronic plc (NYSE: MDT) announced today it will report financial results for Medtronic, Inc.'s third quarter of its fiscal year 2015 on Tuesday, February 17, 2015. A news release will be issued at approximately 6:15 a.m. Central Standard Time and will be available at http://newsroom.medtronic.com. The earnings news release will include summary financial information for Medtronic Inc.'s third fiscal quarter, which ended January 23, 2015.
MDT: 75.26 (+0.33)
Addition of Stent Thrombectomy in Treatment of Acute Ischemic Stroke Patients Reduces Disability in Global Studies
Business Wire - Wed Feb 11, 11:18AM CST
Research presented today at the International Stroke Conference (ISC) in Nashville, Tenn. and published online in The New England Journal of Medicine (NEJM) found that the addition of the Solitaire(TM) Device stent thrombectomy procedure to current pharmaceutical treatment significantly reduced disability in patients suffering stroke.
MDT: 75.26 (+0.33)
Global Insulin Delivery Devices Market 2014-2018: Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche and Becton, and Dickinson and Co Account for 90% of Global Share
M2 - Wed Feb 11, 9:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/hjxrhm/global_insulin) has announced the addition of the "Global Insulin Delivery Devices Market Outlook 2018" report to their offering. This study thus leads to the proposition that innovation has huge scope in the field of insulin delivery and its analysts have elaborate information on some of the emerging insulin delivery devices. Finally, an analysis of the leading market players provides a holistic understanding to the reader. Players covered include Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche and Becton, and Dickinson and Co. These players together account for more than 90% of the global market. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Global Insulin Market Overview to 2018 4. Industry Trends and Drivers 5. Key Market Restraints 6. Global Insulin Delivery Devices Market Outlook to 2018 7. Insulin Delivery Devices: Current and Future Outlook to 2018 8. Emerging Devices 9. Key Players - Abbott Laboratories - B. Braun Melsungen AG - Becton Dickinson - Eli Lilly - F. Hoffmann La Roche - Insulet Corporation - Johnson and Johnson - Medtronic - Novo Nordisk - Sanofi-Aventis - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/hj...al_insulin
JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87), PODD: 32.00 (-0.07), NVO: 43.76 (+0.61), MDT: 75.26 (+0.33), LLY: 70.56 (+0.03)
Device Maker Medtronic, Inc. Agrees to $2.8 Million Settlement Brought Over False Claims Allegations Involving SubQ Stimulation Procedures, Parker Waichman LLP Comments
PRWeb - Wed Feb 11, 9:04AM CST
Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective medical devices and unapproved medical procedures, is commenting on a recent settlement in a case involving Medtronic Inc. and "SubQ Stimulation" procedures. The case--United States ex rel. Nickel v. Medtronic, Inc. Civ. No. 09 - CV - 0203-S (W.D.N.Y.). (rml) NY--ended with Medtronic agreeing to pay $2.8 Million to Resolve False Claims Act Allegations, according to a February 6, 2015 U.S. Department of Justice (DOJ) report.
MDT: 75.26 (+0.33)
Congratulations Covidien: You Escaped In Time
Chris DeMuth Jr. - Seeking Alpha - Wed Feb 11, 8:19AM CST
Originally published on February 4, 2015 The Shakedown In 2014, Obama vowed to punish tax inverting companies by any means necessary - inside and outside of legislation. He took scalps including Shire (NASDAQ: SHPG ) and Walgreens (NASDAQ: WBA...
VRX: 167.00 (-0.50), WBA: 78.73 (-1.23), MDT: 75.26 (+0.33), COV: 106.71 (-1.36), SHPG: 239.82 (+6.11), SLXP: 152.35 (+3.17), NPSP: 45.88 (+0.03), ABBV: 58.05 (+1.00)
Medtronic Insertable Cardiac Monitors Detect Atrial Fibrillation in Stroke Patients in 'Real-World' Study
Thomson Reuters ONE - Wed Feb 11, 8:12AM CST
Findings Reinforce Patient Benefit of Reveal LINQ in Real-World Setting
MDT: 75.26 (+0.33)
Patient Monitoring Global Market 2015 - Forecast to 2020
M2 - Tue Feb 10, 8:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/vvvf8m/patient) has announced the addition of the "Patient Monitoring Global Market - Forecast to 2020" report to their offering. The global patient monitoring devices market is expected to reach approximately $24 billion by 2019 growing at CAGR of around 8.0%. North America commands the largest share and is expected to register a healthy market share by 2019. APAC is going to be one of the prominent regions for this market in coming years driven by the increased purchasing power and rising population. Patient monitoring is essential part of care process together with administration of therapy. The main aim of monitoring is to make sure that proper care [or] therapy can be given in advance to the arrival of complications. Patient monitoring is essential to take care in emergency and operating rooms, intensive and critical care units and it is extremely useful for recovery rooms, respiration therapy, radiology, outpatient care, and gastroenterology department, Transport, Home and sleep screening applications. Patient monitoring play key role to reduce complications, risks, infections as well assist in providing for patient comfort. Patient monitoring devices market is mainly divided into following segments such as Hemodynamic, neurology, respiratory, Cardiology, fetal and neonatal, multi parameters, remote patient monitors, temperature and weight monitors. Some of the key players in this market are Abbott Laboratories (U.S.), GE Health care (U.K.), Johnson & Johnson, Inc. (U.S.), Covidien (Ireland), Mindray Medical (China), Philips Healthcare (Netherlands), Drager Medical GmbH (Germany), and Roche Diagnostics Limited (Switzerland). Key Topics Covered: 1 Executive Summary 2 Introduction 3 Market Analysis 4 Global Patient Monitoring System Market, By Device 5 Global Patient Monitoring System Market, By End-Users 6 Regional Market Analysis 7 Company Developments 8 Major Company Profiles - Abbott Laboratories - Boston Scientific Corpoartion - Covidien Plc - Ge Healthcare - Johnson & Johnson - Medtronic Inc. - Omron Healthcare, Inc. - Philips Healthcare - Roche Ltd. - St. Jude Medical, Inc. Visit http://www.researchandmarkets.com/research/vvvf8m/patient
BSX: 14.98 (+0.24), JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87), MDT: 75.26 (+0.33), STJ: 67.48 (+0.65)
British Journal of Surgery Publishes Five-Year ClosureFast(TM) Study Results
Thomson Reuters ONE - Tue Feb 10, 8:04AM CST
Results Demonstrate Durability, Effectiveness of Treatment for Chronic Venous Insufficiency
MDT: 75.26 (+0.33)
Global Angiography Devices (Angiography systems, Catheters, Guide-Wires, Balloons, Contrast Media, Accessories) Market 2014-2019
M2 - Tue Feb 10, 5:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/66llkk/angiography) has announced the addition of the "Angiography Devices Market by Technology, Products, Application & End-Users - Global Forecast to 2019" report to their offering. The global angiography devices market is estimated to reach $27.7 billion in 2019, at a CAGR of 4.4% from 2014 to 2019 Angiography is a medical imaging procedure used to visualize blood vessels (arteries and veins) inside the body. Angiography devices are used to diagnose and evaluate many diseases of blood vessels and related conditions, such as injuries, aneurysms (ballooning of a blood vessel), blockages (due to blood clots or plaques), stenosis (narrowing of a blood vessel), congenital (birth-related) heart abnormalities, disorganized blood vessels, and blood supply to tumors. Images captured trough angiography is called as angiograms. The angiography devices market is mainly driven by technological advances, innovative product offerings, and growing aging population and increasing prevalence of vascular diseases. However, the lack of reimbursement for these systems and the presence of stringent regulations are expected to restrain the growth of this market in the forecast period. The angiography devices market in this report is broadly segmented by technology, products, applications, procedures, indications, and end users. The market, by products, is segmented into angiography systems, catheters, guide-wires, balloons, contrast media, vascular closure devices, and accessories. The market by technology is segmented into X-ray, computed tomography, and magnetic resonance angiography. Based on applications the market is segmented as diagnostic and therapeutic. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Angiography Devices Market, By Technology 7 Angiography Devices Market, By Products 8 Angiography Devices Market, By Type Of Application 9 Angiography Devices Market, By Procedure 10 Angiography Devices Market, By Indication 11 Angiography Devices Market, By End-Users 12 Geography Analysis 13 Competitive Landscape 14 Company Profiles - Abbott Vascular - Boston Scientific Corporation - Cordis Corporation (A Jnj Company) - GE Healthcare - Medtronic Inc. - Philips Healthcare - ST. Jude Medical - Shimadzu Corporation - Siemens Healthcare - Toshiba Corporation For more information visit http://www.researchandmarkets.com/research/66...ngiography
BSX: 14.98 (+0.24), MDT: 75.26 (+0.33), STJ: 67.48 (+0.65)
U.S. & European Heart Valve Market Overview 2014
M2 - Tue Feb 10, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/l83sqr/u_s_and_european) has announced the addition of the "U.S. & European Heart Valve Market" report to their offering. The surgical heart valve market consists of both mechanical and tissue heart valves. Tissue heart valves consist of stented, stentless and sutureless tissue heart valves. Stented heart valves have long been the industry standard; however, stentless and sutureless valves are expected to show a strong presence over the forecast period. A sutureless valve differs from traditional tissue heart valves in that it is self-anchoring and thus does not need to be sutured in place. Thus, sutureless heart valves require a shorter procedure time than traditional tissue heart valves, and are able to be delivered minimally invasively. The sutureless heart valve market is expected to increase its share approximately threefold. The market has a competitive landscape with each competitor having quality and clinically supported products available. A critical note for the surgical heart valve market is that the growth of the transcatheter heart valve implantation device market has not had a substantial impact on the demand for surgical heart valves, indicating that the various valve technologies treat different patient populations. Key Topics Covered: 1. Research Methodology 2. Heart Valve Device And Procedure Overview 3. U.S. Tissue Heart Valve Market 4. European Tissue Heart Valve Market 5. U.S. Mechanical Heart Valve Market 6. European Mechanical Heart Valve Market 7. U.S. Annuloplasty Repair Device Market 8. European Annuloplasty Repair Device Market 9. U.S. Transcatheter Mitral Valve Repair Device Market 10. European Transcatheter Mitral Valve Repair Market 11. U.S. Transcatheter Heart Valve Implantation Device Market 12. European Transcatheter Heart Valve Implantation Device Market Companies Mentioned - Cardiac Dimensions - Cardiosolutions - CryoLife - Direct Flow Medical - Edwards LifeSciences - Endovalve Inc - JenaValve - JenaValve Technology - Medtronic - MiCardia - Sandra Medical - Sorin - St. Jude Medical For more information visit http://www.researchandmarkets.com/research/l8...d_european
MDT: 75.26 (+0.33), STJ: 67.48 (+0.65), EW: 134.23 (+1.89), CRY: 11.30 (-0.10)
Medtronic's Pipeline Flex Embolization Device Gets FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 4:05PM CST
Medtronic announced the FDA approval for its Pipeline Flex embolization device (the next-generation flow diversion device).
ICUI: 88.98 (+0.42), NXTM: 17.56 (-0.05), MDT: 75.26 (+0.33), ABAX: 60.93 (+0.65)
